Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Novel AI Boosts Geographic Atrophy Clinical Trial Efficiency
A new artificial intelligence (AI) system developed by researchers from UCL and Moorfields Eye Hospital could potentially revolutionize the recruitment process for clinical trials aimed at treating Geographic Atrophy (GA), an advanced form of dry age-related macular degeneration (AMD) that…
NVISION Eye Centers Partners with Parkhurst NuVision
NVISION Eye Centers, a prominent provider of eye care services nationwide, announced a strategic collaboration with Parkhurst NuVision of San Antonio, Texas, through its subsidiary NVision Clinical Research, LLC. This partnership aims to advance clinical trials in ophthalmology drug development,…
4DMT Receives FDA Clearance of IND for GA Treatment
4D Molecular Therapeutics (4DMT) announced the FDA clearance of its investigational new drug application (IND) for 4D-175, an R100 vector-based intravitreal genetic medicine intended for treating geographic atrophy (GA) in patients. Phase 1 GAZE Clinical Trial Details The phase 1…
Novartis’ AMD Drug Linked to Rare Retinal Side Effects
Two recent studies have found that a drug called brolucizumab, which was approved in 2019 and developed by Swiss pharmaceutical company Novartis AG to treat wet age-related macular degeneration (AMD), can cause rare retinal side effects due to its interaction…
DORC Receives FDA Clearance for Eva Nexus System
DORC International has announced 510(k) market clearance and the launch of the Eva Nexus. According to DORC, the Eva Nexus features multiple innovations to improve performance, efficiency, and stability for retina surgeons, including Smart IOP for anterior and posterior chamber stability; DORC’s trocar cannula system with HI-FLOW infusion…
Primary Open Angle Glaucoma (POAG)
A subtype of glaucomas known as primary open angle glaucoma (POAG) is characterized by an open, seemingly normal anterior chamber angle and elevated intraocular pressure (IOP), with no additional underlying disease. Secondary glaucoma is a condition where the elevated IOP…
Harrow Starts Triesence Relaunch Strategy
Harrow Pharmaceuticals announced its efforts to relaunch Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL in the United States market. The company announced the successful manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches required for the relaunch.…
FDA Grants Breakthrough and RMAT Status to Aurion’s AURN001
Aurion Biotech has been granted Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) Designation by the FDA for AURN001, Aurion’s innovative allogeneic cell therapy candidate designed to treat corneal edema secondary to corneal endothelial disease. Expediting Development and…
Oculis’ Licaminlimab Shows Promise in Phase 2B Trial for DED
Oculis Holding announced positive topline results from its phase 2b RELIEF trial, shedding light on the efficacy of licaminlimab, an innovative anti-TNFα biologic eye drop, in addressing dry eye disease (DED). Licaminlimab’s established dual mechanism of action, boasting both anti-inflammatory…
Metformin Found Ineffective Against Geographic Atrophy
In the quest to find effective treatments for eye diseases, the METformin for the MINimization of Geographic Atrophy Progression (METforMIN) trial sought to evaluate the efficacy of oral metformin in slowing the progression of geographic atrophy (GA) and its effects…